Analyst Price Targets — ANIP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 11:28 am | Vamil Divan | Guggenheim | $119.00 | $78.25 | StreetInsider | ANI Pharmaceuticals (ANIP) PT Lowered to $119 at Guggenheim |
| August 10, 2026 10:58 am | — | Canaccord Genuity | $90.00 | $78.25 | TheFly | ANI Pharmaceuticals price target lowered to $90 from $91 at Canaccord |
| July 16, 2026 8:11 pm | — | Canaccord Genuity | $91.00 | $81.92 | TheFly | ANI Pharmaceuticals initiated with a Hold at Canaccord |
| January 16, 2026 11:32 am | Vamil Divan | Guggenheim | $124.00 | $85.29 | StreetInsider | ANI Pharmaceuticals (ANIP) PT Raised to $124 at Guggenheim |
| October 9, 2025 1:23 pm | — | Truist Financial | $90.00 | $91.63 | TheFly | ANI Pharmaceuticals price target raised to $90 from $77 at Truist |
| September 17, 2025 2:17 pm | Brandon Folkes | H.C. Wainwright | $121.00 | $95.36 | TheFly | ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright |
| September 8, 2025 11:46 am | Vamil Divan | Guggenheim | $114.00 | $95.20 | TheFly | ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim |
| August 8, 2025 3:00 pm | David Amsellem | Piper Sandler | $94.00 | $81.13 | TheFly | ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler |
| March 5, 2025 1:58 pm | — | Guggenheim | $86.00 | $59.68 | TheFly | ANI Pharmaceuticals price target raised to $86 from $84 at Guggenheim |
| September 18, 2024 9:14 am | Gary Nachman | Raymond James | $83.00 | $61.23 | TheFly | ANI Pharmaceuticals price target raised to $83 from $81 at Raymond James |
Latest News for ANIP
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026.
Aurora Investment Counsel bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) in the undefined quarter, according to its most recent filing with the SEC. The fund bought 26,890 shares of the specialty pharmaceutical company's stock, valued at approximately $2,226,000. Aurora Investment Counsel owned 0.12% of ANI Pharmaceuticals at the end of
Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANIP.
U.S. House Trading
No House trades found for ANIP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.